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Nosocomial bloodstream infections (nBSIs) are an important cause of morbidity and mortality. Data from
a nationwide, concurrent surveillance study, Brazilian SCOPE (Surveillance and Control of Pathogens of
Epidemiological Importance), were used to examine the epidemiology and microbiology of nBSIs at 16
Brazilian hospitals. In our study 2,563 patients with nBSIs were included from 12 June 2007 to 31 March 2010.
Ninety-five percent of BSIs were monomicrobial. Gram-negative organisms caused 58.5% of these BSIs,
Gram-positive organisms caused 35.4%, and fungi caused 6.1%. The most common pathogens (monomicrobial)
were Staphylococcus aureus (14.0%), coagulase-negative staphylococci (CoNS) (12.6%), Klebsiella spp. (12.0%),
and Acinetobacter spp. (11.4%). The crude mortality was 40.0%. Forty-nine percent of nBSIs occurred in the
intensive-care unit (ICU). The most frequent underlying conditions were malignancy, in 622 patients (24.3%).
Among the potential factors predisposing patients to BSI, central venous catheters were the most frequent
(70.3%). Methicillin resistance was detected in 157 S. aureus isolates (43.7%). Of the Klebsiella sp. isolates,
54.9% were resistant to third-generation cephalosporins. Of the Acinetobacter spp. and Pseudomonas aeruginosa
isolates, 55.9% and 36.8%, respectively, were resistant to imipenem. In our multicenter study, we found high
crude mortality and a high proportion of nBSIs due to antibiotic-resistant organisms.
Nosocomial bloodstream infections (nBSIs) are an impor-
tant cause of morbidity and mortality (29). The incidences of
bloodstream infections (BSIs) are varied (1 to 36%) in differ-
ent studies (8, 28). The crude mortality is high, particularly for
intensive-care unit (ICU) patients (23).
Current guidelines recommend broad-spectrum combina-
tion therapy with more than two antibiotics as the initial em-
pirical therapy for some types of infections in patients at risk of
being infected with resistant organisms (1). All antibiotics can
potentially exert selective pressure and thereby drive resis-
tance, yet appropriate empirical antimicrobial therapy is im-
portant, since it can decrease mortality in critically ill patients
(12, 14).
The rates of antimicrobial resistance among pathogens caus-
ing health care-associated infections are increasing, principally
among Gram-negative organisms (Pseudomonas aeruginosa,
Acinetobacter baumannii, and Klebsiella pneumoniae) (3). In-
deed this increase in antimicrobial resistance demonstrates a
need for surveillance programs to define the species distribu-
tion and the resistance patterns of pathogens causing nBSIs,
ultimately helping clinicians to choose the most appropriate
antimicrobial therapy for hospitalized patients (29).
There are differences in surveillance programs in different
parts of the world with regard to methodologies and popula-
tions studied (e.g., ICU patients, neutropenic patients, and
hemodialysis patients) (13, 27, 29). The purpose of this study
was to evaluate the epidemiological features of nBSIs in Brazil
and the species distribution and antimicrobial susceptibility of
the pathogens, using the same methodology as the U.S. Sur-
veillance and Control of Pathogens of Epidemiologic Impor-
tance (SCOPE) program (29).
MATERIALS AND METHODS
Study design. The Brazilian SCOPE (BrSCOPE) is based at Universidade
Federal de Sao Paulo, Sao Paulo, Brazil, and includes 16 hospitals of various
sizes that are geographically dispersed throughout the five different regions of
Brazil (north, northeast, middle-east, southeast, and south). Clinical data were
concurrently collected by local infection control practitioners using a standard-
ized case report form and forwarded to the coordinating center, along with each
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microbiological isolate. The study period reported on here is 12 June 2007 to 31
March 2010.
A nosocomial BSI was diagnosed if 1 or more cultures of blood sampled at
least 48 h after admission yielded a pathogenic organism. If the bloodstream
isolate was a potential skin contaminant (e.g., diphtheroids, Propionibacterium
spp., Bacillus spp., coagulase-negative staphylococci, or micrococci), the pres-
ence of an intravascular catheter and the initiation of targeted antimicrobial
therapy were required for the diagnosis, as well as at least 1 of the following
findings: temperature of38.0°C or36°C, chills, and/or systolic blood pressure
of 90 mm Hg. BSI episodes that represented relapses were excluded. We
studied the data from all eligible episodes of BSI.
The data that were routinely collected included the patient’s age, sex, location
at the onset of BSI (ICU versus non-ICU ward), clinical service at the onset of
BSI, and predisposing clinical conditions, as well as the identifications and
antimicrobial susceptibilities of the causative pathogens and status at discharge.
Predisposing clinical conditions that were routinely recorded included neutro-
penia (defined as an absolute neutrophil count of 1,000/l), peritoneal dialysis
or hemodialysis, and presence of intravascular catheters (i.e., central lines, arte-
rial catheters, or peripheral intravenous catheters). Secondary BSIs were re-
garded as those with a clear source of bacteremia other than a central line.
Sources of secondary BSI were identified by cultures of samples (urine, tracheal
secretions, intra-abdominal samples, etc.) obtained from distant sites that yielded
the same pathogen with an identical resistance pattern. Distant sites were sites
where an infection was diagnosed other than a central line (pneumonia, urinary
tract infection, abdominal infection, etc.).
Microbiological methods. Blood cultures were processed at the participating
hospitals. The identification of blood isolates and susceptibility testing were done
by the routine methods in use at the affiliated laboratories. All affiliated labora-
tories were Brazilian Society of Clinical Pathologists certified, and all microbi-
ological methods used were consistent with current CLSI recommendations (7).
Data from all hospitals were used for analysis, and denominators for individual
antimicrobial agents may vary, because not all hospitals test and report all drugs.
At the reference laboratory, the Special Microbiology Laboratory of Universi-
dade Federal de Sa˜o Paulo, samples identified by manual methods were sub-
jected to reidentification and antimicrobial susceptibility testing by a Phoenix BD
automated system. MIC determination by Etest for oxacillin and carbapenems
and agar dilution for vancomycin were done to confirm resistant phenotypes.
Molecular tests were applied to selected resistant strains of methicillin-resis-
tant Staphylococcus aureus (MRSA) (mecA gene; staphylococcal cassette chro-
mosome mec [SCCmec] characterization was according to the method of Zhang
et al. [30] and Milheiric¸o et al. [19], and molecular typing was done by pulsed
field gel electrophoresis [PFGE]), Enterococcus spp. (vanA and vanB genes) (10),
K. pneumoniae (blaTEM, blaCTX, and blaSHV [6] and blaKPC [20] genes), Acin-
etobacter spp. (blaOXA23 and blaOXA51 genes) (25), and P. aeruginosa (blaIMP,
blaVIM, and blaSPM genes) (18).
Statistical analysis. The results were expressed as the mean  standard de-
viation (SD) or as a proportion of the total number of patients or isolates. For
continuous variables, mean values were compared, using two sample t tests for
independent samples. Differences in proportions were compared using a chi-
square test or Fisher’s exact test, as appropriate. All tests of significance were 2
tailed;  was set at 0.05. All statistical analyses were done using SPSS software
(SPSS).
RESULTS
Study population and patient characteristics. During the
2.8-year study period, a total of 2,563 infections with 2,688
organisms were reported by the 16 participating hospitals. Of
these, 342 clinically significant episodes of BSI (13.3%) were
identified in pediatric patients (16 years of age). The patients
had a mean age of 50.6  24.8 years (range, 0 to 97 years).
Fifty-six percent of the patients were male (Table 1).
Approximately one-half (49%) of hospital-acquired BSIs oc-
curred in the ICU. The most frequent underlying conditions
(recorded as diagnoses at admission) were malignancy, in 622
patients (24.3%); neurologic conditions, in 309 patients
(12.1%); cardiovascular conditions, in 292 patients (11.4%);
gastroenterology conditions, in 251 patients (9.8%); respira-
tory conditions, in 230 patients (9.0%); and renal conditions, in
220 patients (8.6%), as shown in Table 1.
Among the potential factors predisposing patients to BSI,
intravascular devices were the most frequent. Central venous
catheters were present in 1,803 (70.3%) patients, peripheral
intravenous catheters were in place in 701 patients (27.4%),
and arterial catheters were in place in 52 patients (2.0%).
Urinary catheters were present in 1,051 patients (41.0%). A
total of 143 patients (5.6%) were receiving parenteral nutri-
tion, and 256 patients (10.0%) required dialysis at the onset of
BSI. Most of these patients underwent hemodialysis (228 pa-
tients versus 28 who underwent peritoneal dialysis). Mechan-
ical ventilation was necessary for 866 patients (33.8%). Over-
all, 1,024 patients died during hospitalization, accounting for a
crude mortality rate of 40.0% (Table 1).
Microbiological features. Five percent of all episodes of BSI
(n  116) were polymicrobial. Of 2,447 monomicrobial epi-
sodes, a total of 1,432 (58.5%) were caused by Gram-negative
organisms, 867 (35.4%) by Gram-positive organisms, and 148
(6.1%) by fungi, of which 137 (92.6%) were Candida spp.
(Table 1).
The rank order of the five major pathogens (Table 2) shows
that S. aureus was the principal organism responsible for nBSIs
(15.4%), followed in rank by coagulase-negative staphylococci
(CoNS) (13.4%), Klebsiella spp. (13.2%), Acinetobacter spp.
(12.5%), and P. aeruginosa (8.9%). CoNS, Acinetobacter spp.,
and Candida spp. were more likely to be isolated from patients
in ICUs (P  0.001), as were enterococci (P  0.05), whereas
S. aureus and Klebsiella spp. were more common in patients in
wards (P  0.001 and P  0.05, respectively). No significant
differences were seen for P. aeruginosa, Enterobacter spp., Ser-
ratia spp., and Proteus spp. (Table 2).
When stratified by clinical service (Table 3), the following
patterns emerged: Klebsiella spp. and S. aureus were the most
TABLE 1. Characteristics of the 2,563 patients with nBSIs among
16 Brazilian hospitals
Parameter No. (%)
Patient demographics
Age (yr; mean  SD) ......................................................... 50.6  24.8
Male ......................................................................................1,438 (56.1)
ICU setting...........................................................................1,257 (49.0)
Monomicrobial infection ....................................................2,447 (95.5)
Organisms (n  2,447)
Gram-negative .....................................................................1,432 (58.5)
Gram-positive ...................................................................... 867 (35.4)
Fungi ..................................................................................... 148 (6.1)
Underlying conditions
Malignancy ........................................................................... 622 (24.3)
Neurologic ............................................................................ 309 (12.1)
Cardiovascular ..................................................................... 292 (11.4)
Gastroenterology ................................................................. 251 (9.8)
Respiratory........................................................................... 230 (9.0)
Renal..................................................................................... 220 (8.6)
Potential risk factors
Central venous catheter......................................................1,803 (70.3)
Urinary catheter ..................................................................1,051 (41.0)
Ventilator ............................................................................. 866 (33.8)
Crude mortality ...................................................................1,024 (40.0)
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frequently isolated pathogens for all services, except neurosur-
gery, where Acinetobacter spp., P. aeruginosa, and CoNS were
more frequently isolated.
In patients with monomicrobial BSI, the crude mortality
ranged from 31.0 and 32.0 for S. aureus and CoNS, respectively
(Table 2), to 52.1% and 68.8% for Acinetobacter spp. and
Candida spp., respectively. In ICU patients, the crude mortal-
ity ranged from 46.5% and 48.2% for CoNS and S. aureus,
respectively (Table 2), to 65.5% and 85.9% for Acinetobacter
spp. and Candida spp., respectively. In patients with polymi-
crobial BSI, the crude mortality was 45.7%.
The mean time from hospital admission to onset of BSI due
to the major pathogens ranged from 21 days and 22 days for
Acinetobacter spp. and S. aureus, respectively, to 32 days for
Pseudomonas spp. and enterococci.
Primary BSI, in which no source could be determined, was
seen in 1,143 patients (44.6%). Secondary BSI originated from
the lower respiratory tract in 362 patients (14.1%) and from
the urinary tract in 186 patients (7.3%).
Of the 137 Candida isolates causing monomicrobial nBSI,
nonalbicans species were more common than Candida albi-
cans, accounting for 65.7%. The rank order of the major Can-
dida spp. isolated was C. albicans (34.3%), Candida parapsilosis
(24.1%), Candida tropicalis (15.3%), Candida spp. (10.9%),
Candida glabrata (10.2%), Candida krusei (1.5%), Candida pel-
liculosa (1.5%), Candida lusitaniae (0.7%), Candida famata
(0.7%), and Candida guilliermondii (0.7%). Crude mortality
was lowest for C. parapsilosis infection (51.5%) and highest for
C. krusei, C. pelliculosa, and C. lusitaniae (100%).
Antimicrobial susceptibility. Methicillin resistance was de-
tected in 359 S. aureus isolates (43.7% of the tested isolates)
and in 317 CoNS (86.4%). The proportion of S. aureus isolates
with methicillin resistance was not significantly higher among
ICU patients than among ward patients (49.3% versus 39.9%;
P  0.08). The first 62 samples of MRSA were confirmed by
PCR for the mecA gene, and the SCCmec characterization
revealed that 46.7% belonged to SCCmec type III, 24.1% to
SCCmec type II, and 16.1% to SCCmec type IV. The SCCmec
type III isolates were grouped as belonging to the Brazilian
epidemic clone by PFGE. Three isolates carrying SCCmec type
II showed 100% similarity to the New York-Japan clone.
Vancomycin resistance was found in 25% of 104 enterococ-
TABLE 3. Distribution of nBSIs and most frequently isolated
pathogens causing BSIs, by clinical service
Clinical service, class of BSI, and pathogena No. (%) of BSIs
Internal medicine
All BSIs........................................................................507 (19.8)b
Monomicrobial BSIs
S. aureus ...................................................................134 (26.4)
CoNS ........................................................................ 86 (17.0)
Klebsiella spp. .......................................................... 67 (13.2)
Adult hematology/oncology
All BSIs........................................................................141 (5.5)b
Monomicrobial BSIs
Klebsiella spp. .......................................................... 35 (24.8)
S. aureus ................................................................... 27 (19.2)
CoNS ........................................................................ 15 (10.6)
General surgery
All BSI .........................................................................137 (5.3)b
Monomicrobial BSIs
Klebsiella spp. .......................................................... 29 (21.2)
S. aureus ................................................................... 24 (17.5)
Acinetobacter spp..................................................... 19 (13.9)
Pediatric
All BSIs........................................................................ 71 (2.8)b
Monomicrobial BSIs
S. aureus ................................................................... 13 (18.3)
Acinetobacter spp..................................................... 11 (15.5)
Klebsiella spp. .......................................................... 10 (14.1)
Neurosurgery
All BSIs........................................................................ 71 (2.8)b
Monomicrobial BSIs
Acinetobacter spp..................................................... 10 (14.1)
P. aeruginosa ............................................................ 10 (14.1)
CoNS ........................................................................ 10 (14.1)
Pediatric hematology/oncology
All BSIs........................................................................ 60 (2.3)b
Monomicrobial BSIs
CoNS ........................................................................ 19 (31.7)
Klebsiella spp. .......................................................... 9 (15.0)
Acinetobacter spp..................................................... 7 (11.7)
Cardiothoracic surgery
All BSIs........................................................................ 39 (1.5)b
Monomicrobial BSIs
Klebsiella spp. .......................................................... 7 (18.0)
S. aureus ................................................................... 6 (15.4)
Acinetobacter spp..................................................... 5 (12.8)
a The three pathogens most commonly isolated in each service.
b Percentage of the total of 2,563 BSIs at all study hospitals.
TABLE 2. Distribution of pathogens most commonly isolated from monomicrobial nBSIs and associated crude mortality rates for all patients
in ICUs and patients in non-ICU wards
Pathogen
% BSI (rank) Crude mortality (%)
Total (n  2,447) ICU (n  1,196) Non-ICU (n  1,251) Total (n  971) ICU (n  656) Non-ICU (n  315)
S. aureus 15.4 (1) 12.8 (3)a 17.9 (1) 31.0 48.2 24.0
CoNS 13.8 (2) 16.6 (1)a 11.2 (3) 32.0 46.5 23.2
Klebsiella spp. 13.2 (3) 11.8 (4)b 14.5 (2) 34.7 55.2 24.8
Acinetobacter spp. 12.5 (4) 15.2 (2)a 10.0 (4) 52.1 65.5 39.6
P. aeruginosa 8.9 (5) 10.0 (5) 7.9 (5) 48.9 61.5 39.0
Enterobacter spp. 6.1 (6) 5.8 (7) 6.4 (6) 30.2 61.4 17.1
Candida spp. 5.6 (7) 7.4 (6)a 3.9 (7) 68.6 85.9 53.4
Enterococcus spp. 4.5 (8) 5.5 (8)b 3.6 (9) 49.5 64.2 36.2
Serratia spp. 3.5 (9) 3.2 (9) 3.8 (8) 40.0 60.0 29.1
Proteus spp. 1.6 (10) 1.8 (10) 1.6 (10) 44.7 61.1 30.0
a P  0.001 for patients in ICU vs. patients in non-ICU wards.
b P  0.05 for patients in ICU vs. patients in non-ICU wards.
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cal isolates overall (Table 4), with 55.6% of Enterococcus fae-
cium isolates and 17.6% of Enterococcus faecalis isolates resis-
tant. The vanA gene was detected in 11 and 17 samples of E.
faecalis and E. faecium, respectively. The vanB gene was not
detected in these vancomycin-resistant isolates.
Antimicrobial resistance levels for the most common Gram-
negative organisms causing nosocomial BSIs are shown in Ta-
ble 5. Relatively high proportions of Klebsiella spp. displayed
resistance to ampicillin-sulbactam, piperacillin-tazobactam,
ceftazidime, and cefepime (54.5%, 33.5%, 54.4%, and 50.2%,
respectively). Resistance to imipenem and meropenem was
seen in 0.3% and 1.3% of the isolates. The molecular analysis
of 94 extended-spectrum -lactamase (ESBL)-positive isolates
revealed the presence of blaTEM, blaCTX, and blaSHV genes in
84 (89.3%), 86 (91.4%), and 68 (72.3%) strains, respectively.
Among the carbapenem-resistant isolates, we detected the
blaKPC gene in 3 isolates.
For Acinetobacter spp., cephalosporins, aminoglycosides,
fluoroquinolones, and carbapenems were not active against
50% of the isolates tested. We performed molecular analysis
in 112 isolates resistant to carbapenems, and we detected the
blaOXA23 gene in 85 isolates (75.9%).
Of the P. aeruginosa isolates, 33.9%, 36.6%, 42.9%, 36.8%,
and 35.8% were resistant to piperacillin-tazobactam, ceftazi-
dime, cefepime, imipenem, and meropenem, respectively. We
detected the blaIMP gene in 6 (10%) isolates and the blaSPM
gene in 24 (41%) isolates out of 59 carbapenem-resistant P.
aeruginosa isolates.
DISCUSSION
Nationwide surveillance studies focusing on nosocomial in-
fections are important tools that can discover specific issues
related to antimicrobial resistance. Similar studies have been
conducted in the United States and Europe, and relevant con-
clusions could be drawn from the data obtained (27, 29). The
strength of such studies depends on the high correlation be-
tween etiologic agents and infection causation. As a result,
bloodstream infection surveillance studies are preferable.
Rigid and standardized clinical diagnostic criteria make data
reliable and realistic, avoiding confounding colonizing agents
not directly related to clinical disease.
Brazil is a country with more than 150 million inhabitants
and a total surface area larger than 8,500,000 km2. In addition
to its large area, the country has heterogeneous sociodemo-
graphic indicators, with wealthier regions concentrated in the
southern part of the country. Although the majority of the
population depends on the public health care system, an in-
creasing fraction is being managed by private facilities. Hetero-
geneity is also reflected in health care practices at the level of
nosocomial-infection management. As a result, different pat-
terns of antimicrobial resistance and antimicrobial use may
emerge within the country. Also, due to its intrinsic character-
istics, etiologic agents and their respective antimicrobial sus-
ceptibilities may differ from the data in other countries.
A knowledge of the Brazilian data is of paramount im-
portance for determining regional and national prevention
and treatment strategies for nosocomial infections. Unlike
previous nationwide network surveillance studies, the Bra-
zilian SCOPE Study, similar to the U.S. SCOPE Study (29),
is representative of the whole country, including data from
its 5 different geographical regions. Also, standardized cri-
teria for BSI were applied, conferring reliability for com-
parison with other studies.
Comparing Brazilian with American data, we found similar
cohorts of patients, with very similar proportions of infection
attributed to a central line, similar proportions of BSI origi-
nating in the ICU, and similar mean age and gender distribu-
tions. One striking difference was the observed bacterial etiol-
ogy, with a much higher prevalence of Gram-negative versus
Gram-positive bacteria (59% versus 34%). This finding was
also seen in the EPIC II study (27), where the prevalence of
Gram-negative pathogens in ICUs was 70% in South America
compared to 49% in North America, considering all bacterial
isolates from different body sites. As a tropical country, Brazil
has higher average temperatures than the United States. In the
1970s and 1980s, some studies related higher temperatures (17,
24) to peak occurrences of infections, mainly due to P. aerugi-
nosa. Recently, Perencevich et al. (22) in Maryland have re-
ported higher rates of isolation of nosocomial Gram-negative
bacteria (both fermentative and nonfermentative bacteria) in
spring/summer than in fall/winter and an inverse relation for
Gram-positive agents. Some previous studies point to the en-
hanced contact with water during warm weather to account for
TABLE 5. Rates of antimicrobial resistance among Gram-negative
organisms most frequently isolated from patients with
nosocomial bloodstream infections
Antimicrobial
druga
K. pneumoniae A. baumannii P. aeruginosa
No. of
isolates
%
Resistant
No. of
isolates
%
Resistant
No. of
isolates
%
Resistant
Amp-Sul 178 54.5 265 34.7 ND
Pip-Tazo 281 33.5 148 75.7 174 33.9
Cefazolin 261 53.3 NDb ND
Ceftriaxone 202 55.4 ND ND
Ceftazidime 237 54.4 293 70.0 205 36.6
Cefepime 307 50.2 291 77.7 205 42.9
Imipenem 297 0.3 290 55.9 212 36.8
Meropenem 225 1.3 289 56.4 201 35.8
Ciprofloxacin 282 36.2 278 73.4 193 45.6
Gentamicin 290 30.7 272 51.8 184 45.7
a Amp-Sul, ampicillin-sulbactam; Pip-Tazo, piperacillin-tazobactam.
b ND, not done.
TABLE 4. Rates of antimicrobial resistance among Gram-positive
organisms most frequently isolated from patients with
nosocomial bloodstream infections
Antimicrobial
drug
S. aureus CoNS Enterococcus spp.
No. of
isolates
%
Resistant
No. of
isolates
%
Resistant
No. of
isolates
%
Resistant
Ampicillin NDa ND 106 21.7
Methicillin 359 43.7 317 86.4 ND
Cefazolin 163 34.4 162 85.2 ND
Vancomycin 360 0 329 0.3 104 25.0
Teicoplanin 72 0 124 1.6 31 32.3
Linezolid 148 0 227 0.4 81 1.2
Ciprofloxacin 262 38.2 255 69.0 36 47.2
Clindamycin 359 47.4 323 75.9 ND
Gentamicin 322 31.7 286 59.8 88 43.2
a ND, not done.
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this increase, but the theories are speculative rather than sci-
entifically proven. Another possible explanation is the higher
frequency of BSI episodes secondary to pulmonary and urinary
sources than in the American study. On the other hand, irre-
spective of the cause, the prevalence of Gram-negative bacte-
ria in Brazil has practical importance, especially when dealing
with the issue of empirical treatment of suspected BSI, where,
according to the present data, an agent directed at Gram-
negative coverage is mandatory.
An even more striking difference is the very high percentage
of infection due to P. aeruginosa and Acinetobacter spp. in the
Brazilian cohort (21% versus 6%). However, it is important to
mention that the U.S. SCOPE study occurred almost 10 years
ago, and there have been increases in Acinetobacter infections
in U.S. hospitals in recent years (11, 26). One other possible
explanation is that the higher baseline prevalence of Gram-
negative bacteria is related to enhanced use of anti-Gram-
negative antibiotics, selecting for bacteria prone to develop
multidrug resistance, such as nonfermentative Gram-negative
bacteria. Also, the predilection for the respiratory tract of
isolates of P. aeruginosa and Acinetobacter is another possible
explanation. Again, the high prevalence of these agents may
have a serious impact on antibiotic management, creating a
vicious cycle of heavy use and resistance development.
Another important difference is the higher prevalence of
nonalbicans Candida spp. in the Brazilian cohort. Although
greater use of fluconazole is a possible explanation, the
Brazilian cohort had a higher percentage of infections due
to C. parapsilosis (24% versus 11% of all Candida infec-
tions). This could reflect less than optimal care for central
lines in the Brazilian cohort, since the association of C.
parapsilosis with catheter-related bloodstream infection is
well documented (4, 9).
Antibiotic resistance within the group of Gram-negative bac-
teria is worrisome, especially regarding P. aeruginosa and A.
baumannii. Rates as high as 56% resistance to carbapenems
for Acinetobacter and 35% for P. aeruginosa are among the
highest in the world’s literature and have several implications
for clinical practice (2, 15). Since resistance to carbapenems is
usually associated with multidrug resistance (5), very few op-
tions remain viable. In some instances, polymyxins are the last
alternative (21), and these drugs, already widely used in Brazil
(16), could be considered in empirical therapy for the sub-
group of patients prone to develop BSI due to these agents.
Klebsiella spp. were the main enterobacteria isolated in our
study, with a high level of ESBL-positive strains. KPC carbap-
enemase carriers were recently detected in Brazil (20).
S. aureus is the main cause of the bloodstream infections in
the study, with a high level of methicillin resistance. Our mo-
lecular data reveal that SCCmec type III, belonging to the
Brazilian epidemic clone, is still the most prevalent in our
nBSIs; however, we show the introduction of SCCmec type II,
and particularly of SCCmec type IV, S. aureus isolates in the
hospital setting.
Very high crude mortality rates related to BSI were observed
compared to the U.S. SCOPE Study (29). Antimicrobial ap-
propriateness in BSI is a major factor related to survival (21)
and could not be evaluated in the present study. This may play
a role, since the rates of mortality caused by pathogens are
considerably different in the two studies. On the other hand,
the study population composition may have an impact on the
overall results. For instance, more patients with malignancy
(24% versus 17%) and a higher proportion of multidrug-resis-
tant organisms are present in the Brazilian cohort.
In conclusion, our study discloses a pattern of BSI in Bra-
zilian hospitals that is considerably different from the Ameri-
can experience. A very high proportion of aerobic Gram-neg-
ative bacteria, very high rates of resistance to carbapenems by
nonfermentative Gram-negative bacteria, higher mortality
rates, and a shift to nonalbicans species of Candida were noted,
and such findings may help Brazilian hospitals to develop their
own guidelines for the treatment of BSIs.
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